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Abstract Lung cancer is a major public health problem
causing more deaths than any other cancer. A better under-
standing of the biology of this disease and improvements in
treatment are greatly needed. Increasing evidence supports
the concept that a rare and specialized population of cancer
cells, so-called cancer-initiating cells with stem cell-like char-
acteristics, is responsible for tumor growth, maintenance, and
recurrence. Cancer-initiating cells also exhibit characteristics
that render them resistant to both radiation and chemotherapy,
and therefore they are believed to play a role in treatment
failure. This has led to the hypothesis that traditional therapies
that indiscriminately kill tumor cells will not be as effective as
therapies that selectively target cancer-initiating cells. Investi-
gating putative cancer-initiating cells in lung cancer will
greatly benefit the understanding of the origins of this disease
and may lead to novel approaches to therapy by suggesting
markers for use in either further isolating this population for
study or for selectively targeting these cells. This review will
discuss (1) lung cancer, (2) stem cells, and the role of cancer-
initiating cells in tumorigenesis; (3) markers and functional
characteristics associated with lung cancer-initiating cells; and
(4) the potential to selectively target this subpopulation of
tumor cells.
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Lung cancer and cancer-initiating cells
Lung cancer is the leading cause of cancer-related deaths
worldwide [1]. Despite recent advances in treatment, the
overall survival of patients with lung cancer remains only
15 % at 5 years, and this declines to less than 2 % in patients
with metastatic disease [2]. For patients with advanced small
cell lung cancer (SCLC), disease survival is 1–2 % [3].
Patients who respond to initial treatment often relapse and
succumb to chemotherapy-resistant tumors [4]. This familiar
clinical scenario is not restricted to lung cancer, but occurs
in several hematological and solid tumors. Hence, new treat-
ments that specifically target chemotherapy-resistant cells
are needed.
The majority of solid tumors are composed of a hetero-
geneous population of cells including a proportion of cells
that are innately chemotherapy-resistant or have gained
resistance through acquired mutations (reviewed in [5]).
As a result, chemotherapy predominantly kills the drug-
sensitive cells, leaving behind a heterogeneous population
of resistant cells, including those that have the potential to
re-populate the tumor or seed new metastatic sites. These
cells are putative cancer-initiating cells (CICs). We believe
that under the selective pressure of chemotherapy the CICs,
which are innately chemo-resistant, are able to produce
progenitor cells which are also resistant to chemotherapy
leading to the development of a treatment resistant tumor.
Evidence for this can be seen in chemotherapy resistant
tumors which have an acquired increased expression of the
multi-drug resistance genes (e.g., MDR1), which encode for
drug efflux pumps. These pumps are highly expressed in
CICs and are thought to be a major factor in their innate
drug resistance [6].
The concept of a specialized population of cells within
tumors termed CICs, or alternatively cancer stem cells or
tumor-initiating cells, has received considerable recent
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interest. CICs represent a subpopulation of transformed
cells, distinct from more “differentiated” tumor cells, and
are thought to be responsible for tumor organization, main-
tenance and progression, and resistance to therapy. CICs
display functional characteristics of stem cells such as the
capacity for self-renewal and the ability to give rise to
differentiated progeny responsible for tumor proliferation.
Putative CICs have been identified in acute myeloid leuke-
mia (AML) [7, 8], and solid tumors of the brain [9, 10] and
breast [11], among others. More recently, lung CICs have
been isolated from human cell lines and patient samples
[12–19]. CICs are posited to share many of the properties
of normal somatic stem cells.
Stem cells and the role of CICs in tumorigenesis
Normal somatic stem cells have the following attributes: (1)
they are capable of self-renewal and repair in adult tissues;
(2) they have the capacity for differentiation and the ability
to generate a large number of multi-lineage progeny; (3)
they are normally quiescent, but can be activated and pro-
liferate in response to various stimuli to maintain tissue
homeostasis; and (4) they have flexibility in applying these
characteristics [20]. Somatic stem cells reside at the top of a
hierarchy of tissue cells. Downstream of the stem cells is the
more differentiated and rapidly proliferating progenitor/tran-
sit-amplifying cell progeny. Progenitor cells are capable of
differentiating into mature cells of various lineages. Differ-
entiated cells are specialized for specific roles and make up
the bulk of the tissue.
Under the appropriate conditions, stem cells may under-
go either asymmetrical division, to give rise to one transit-
amplifying cell and another stem cell, or symmetrical divi-
sion, to give rise to two stem cells or two transit-amplifying
cells [20]. Asymmetric division provides continuation of the
stem cell compartment while also producing the starting
material for production of differentiated cells. Symmetric
division provides flexibility during homeostasis: producing
two stem cells or two transit-amplifying cells may either
increase or decrease the stem cell pool depending on the
needs of the system [21]. It has been suggested that the stem
cell environment or niche may alter the stem cell pool by
influencing how the stem cell divides and the plasticity of
these cells [22]. The lung has a hierarchical organization that
is thought to be regulated through the presence and activity
of lung stem cells [23].
CICs are cancerous cells with many similar attributes as
somatic stem cells including (1) self-renewal capacity, (2)
the ability to differentiate and produce multi-lineage proge-
ny that are tumorigenic and non-tumorigenic, (3) the capac-
ity to establish and maintain tumors, and (4) flexibility in the
application of these processes. Both cell types are long-lived
and exhibit telomerase activity and active anti-apoptotic
pathways [24]. Somatic stem cells and CICs demonstrate
resistance to toxins and chemotherapeutics, often as a result
of expression of the ATP-binding cassette (ABC) membrane
transporter proteins [15, 25], and are believed to be relatively
resistant to radiation due to their low proliferative indexes.
Stem cells and CICs are also motile, thus allowing migration
and homing of somatic stem cells, and metastatic spread for
CICs [26]. Additionally, both somatic stem cells and tumors/
CICs have niches—surrounding environments where bi-
directional interactions between somatic stem cells/CICs
occur that help maintain them.
The origins of CICs are largely unknown (reviewed in
[27]). It has been posited that normal stem cells that have
undergone mutational events leading to a loss of self-renewal
control are the source of CICs, or that transit-amplifying or
differentiated cells that have undergone “de-differentiation,”
acquired a self-renewal capacity, and lost regulation of cellular
division could be the source of CICs (Fig. 1a). The similarity
between somatic stem cells and CICs suggests that fewer steps
might be involved for stem cells to transform into CICs
compared to transit-amplifying or differentiated cells, which
need to gain stem cell-like characteristics. However, the rarity
of stem cells and the relative quiescent nature of somatic stem
cells would suggest that they may be less likely to accumulate
oncogenic mutations compared to transit-amplifying cell
progeny. Regardless of the origin of CICs, they can be iden-
tified and isolated based on certain characteristics.
Self-renewal pathways and stemness genes associated
with CICs
One critical step in the transformation of a normal cell into a
CIC is the acquisition of unregulated self-renewal. This is
often associated with changes in the signaling pathways of
Hedgehog (Hh), Notch, and Wnt/β-catenin, and/or the acti-
vation of “stemness” genes such as Oct-4, Nanog, Sox-2, or
bone morphogenetic proteins (BMPs). Signaling pathways
involved in maintaining CICs self-renewal or “stemness”
may represent potential targets for cancer therapy.
The Hedgehog/Patched pathway is involved in embryonic
growth and cell fate determination. During lung development,
Hh signaling plays a role in lung bud branching morphogen-
esis [28]. Hh signaling has been implicated in regulating
self-renewal of hematopoietic stem cells [29] and myeloid
leukemia cells [30], as well as tumor cells in several solid
tumors. Hh overexpression may lead to uncontrolled prolifer-
ation of tissue stem cells, generating a pool of target cells for
additional oncogenic events leading to acquisition of CICs.
Alterations in the Hh pathway have been reported in a variety
of cancers including medulloblastoma, glioma, stomach, co-
lon, pancreatic cancer, basal cell carcinoma, rhabdomyosar-
coma, breast, prostate, and lung cancer [31].
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The Notch family of transmembrane signaling proteins
(Notch-1, -2, -3, and-4) regulate cell fate and are expressed
in stem cells and transit-amplifying cells [32]. Notch signal-
ing activation, via Jagged-1, is involved in the maintenance
of self-renewal and plasticity for hematopoietic stem cells
[33]. Inappropriate activation of Notch signaling stimulates
proliferation, restricts differentiation and prevents apoptosis
in cancer cells, and is associated with a variety of human
cancers including breast, neuroblastoma, cervical, and lung
[34]. Additionally, Notch signaling has been shown to pre-
serve lung somatic stem cells in an undifferentiated state
inhibiting terminal epithelial differentiation [35, 36].
The Wnt pathway is involved in cell fate determination in
many organs during embryonic development. The Wnt
pathway involves a large number of proteins in a cascade
that ultimately leads to controlling the amount of β-catenin
that reaches the nucleus to activate gene expression. Wnt
signaling has been shown to regulate self-renewal in stem
cells [37]. Evidence from transgenic mouse models demon-
strated Wnt signaling pathway activation in stem cells leading
to epithelial cancers [38]. Additionally, a pro-oncogenic role
for β-catenin, a downstream target of Wnt signaling, has been
described [39]. Drawn together, this indicates the involvement
of Wnt signaling pathway members in the deregulation of
stem cells into CICs. Evidence has emerged that Wnt signal-
ing may play a role in lung tumorigenesis [40].
Induced stem cells are somatic cells that have been reprog-
rammed through forced expression of specific genes to obtain
pluripotent stem cell-like characteristics [41]. This has led to
the identification of “stemness” genes/transcriptional
Fig. 1 Origins of cancer-initiating cells and conventional therapy
versus cancer-initiating cell targeted therapy. a CICs may be derived
from somatic stem cells, progenitor cells, or differentiated cells. So-
matic stem cells may require fewer transformational events than other
cell types to become CICs. These events might include loss of regula-
tion of self-renewal pathways and/or loss of cell division control.
Somatic stem cells can undergo symmetric division to generate two
stem cells, or asymmetric division to generate one stem cell and one
progenitor cell. Progenitor cells may undergo a transforming event
involving re-expression of self-renewal genes and a subsequent loss
of cell division regulation to become CICs. Progenitor cells provide the
starting material for proliferation and differentiation of cells into sev-
eral lineages of differentiated cells. In order to generate a CIC,
differentiated cells may undergo de-differentiation with re-expression
of self-renewal genes and loss of regulation of cell division. b CICs
form and maintain a heterogeneous tumor through rounds of asymmet-
ric and symmetric division and through suppressing or evading host
immune responses. Treatment typically begins soon after clinically
apparent disease is detected. Conventional therapies that target differ-
entiated cells, but spare CICs allow initial debulking of the tumor.
However, tumor ultimately recurs because the rare therapy-resistant
CICs have not been eliminated. These recurrences are often not re-
sponsive to subsequent treatment. Conversely, therapies that target
CICs, but spare differentiated cells, do not appear to greatly debulk
the tumor early on. However, as the CIC pool has been eliminated, the
tumor can no longer maintain itself and ultimately degenerates
Targ Oncol (2013) 8:159–172 161
regulators involved in this process including c-myc, Klf4,
Nanog, BMPs, Sox-2, and Oct-4. Sox-2 and Oct-4 in partic-
ular are involved in regulating self-renewal and pluripotent
potential in stem cells and CICs. Enhanced expression of these
genes, often in association with other functional/phenotypic
markers or characteristics, has been used to characterize CICs
from non-CICs in lung cancer [12–14, 17–19, 42].
Biological markers and functional characteristics of lung
CICs
Various biological markers have been used for isolating and
characterizing lung CICs. These include (1) cell surface
markers such as CD133 and CD44; (2) phenotypic character-
istics such as exclusion of Hoechst 33342 dye (side popula-
tion) and aldehyde dehydrogenase 1 (ALDH1) activity; and
(3) functional characteristics such as chemo- or radiotherapy
resistance, growth as spheroids in serum-free medium, and
tumor initiation in vivo (see Table 1). These characteristics are
often used in concert (in addition to demonstrating activation
of self-renewal pathways and stemness genes) to isolate and
identify putative lung CIC populations.
CIC cell surface markers: CD133 and CD44
CD133 (prominin-1) is a five-transmembrane glycoprotein
initially identified as a marker for isolating CD34+ human
hematopoietic progenitor cells [43, 44]. CD133 has subse-
quently been used to identify and isolate somatic stem/
progenitor cells of neural [45], epithelial [46], and endothe-
lial origin [47], as well as their putative corresponding CICs
[10, 14, 48–51]. The function of CD133 has not been well
described and its ligand is currently unknown. It has been
reported that CD133 may play a role in cell cycle regulation
and proliferation of cells, but not necessarily tumor initiation
[52]. CD133 has been used as a marker to examine lung
CICs. In a study assessing CD133 in lung cancer cells from
patients and cell lines, Chen et al. demonstrated higher
expression of Oct-4 in CD133+ cells compared to CD133−
cells [13]. In that study, Oct-4 expression was demonstrated
to be essential for maintaining stem cell-like properties such
as self-renewal capacity and invasiveness. Compared to
CD133− cells, CD133+ cells were also reported to have
enhanced resistance to conventional treatments and in-
creased in vivo tumor-restoration capacity and proliferation.
Eramo et al. demonstrated that CD133+ cells isolated from
patient lung cancer samples can grow as tumorspheres and
have a tumorigenic potential that is lost upon differentiation
into CD133− cells [14]. In that study, the expression of
CD133 ranged between 0.32 % and 22 % of tumor cells.
CD133+ cells have been reported to have a low frequency in
normal lung cells (<1 %) while a relatively high, but
variable, frequency in most lung cancer samples; 47 out 56
primary lung cancer tissue samples demonstrated CD133
expression ranging from 0.02 % to 35 % [12]. Cells express-
ing CD133 have been described as having a self-renewal
capacity, cisplatin resistance in vitro and in vivo, enhanced
expression of stemness-related markers (Oct-4 and Nanog),
and greater tumorigenicity [12]. However, CD133 is likely
not a universal marker for all lung CICs. Leung et al. did not
detect CD133 in nine out of 10 human non-small cell lung
cancer (NSCLC) cell lines with an ability to induce tumors in
immunocompromised mice [17]. Similarly, Meng et al. dem-
onstrated that both CD133+ and CD133− subpopulations of
two human lung cancer cell lines both contained CICs, calling
into question the exclusive reliance on this marker [53].
CD44 is a cell membrane receptor glycoprotein that binds
hyaluronic acid, is involved in cell adhesion, motility, and
metastases, and, along with P-glycoprotein, has been linked
to multi-drug resistance [54]. CD44 expression has been
associated with up-regulation of other cancer-associated
factors such as transforming growth factor-beta (TGF-β),
genes associated with WNT signaling, cell adhesion mole-
cules, and chemokines [55, 56]. CD44 can affect cell pro-
liferation through its actions as a co-receptor with EGFR
and ErbB family receptor tyrosine kinases [57]. Additional-
ly, CD44 has been linked to enhancing anti-apoptosis
through the PI3K/AKT cascade [58]. CD44 expression has
been associated with human NSCLC cells enriched for CIC-
like properties [17]. Using ten human NSCLC cancer cell
lines, Leung et al. have shown that CD44+ cells have
enhanced CIC properties compared to CD44− cells, includ-
ing enhanced spheroid formation in vitro [17]. Enhanced in
vivo tumor initiation compared to CD44− cells was shown
for sorted CD44+ cells from the H1299, HKULC4, H1650,
and HCC827 cell lines, with as few as 10,000 cells being
capable of tumor initiation by days 30–68, compared to no
tumors formed from the CD44− cells by day 90. For H1299
cells, CD44+ or unsorted cells were shown to have en-
hanced cisplatin resistance compared to CD44− cells.
CD44+ cells, either freshly sorted or from CD44+-initiated
tumors, showed expression of pluripotency/stemness genes
(OCT4, NANOG, SOX2) not expressed by CD44− cells.
However, CD44 expression was only detected in six of 10
cell lines examined [17], calling into question the exclusive
reliance on this marker. The heterogeneity of CIC cell sur-
face markers between tumors has led to the investigation of
functional markers to identify CICs.
Functional markers of lung CICs: side population
and ALDH1 activity
A functional marker is a physical marker that can be used to
target or isolate the CIC and is associated with a functional
characteristic of CICs. One functional characteristic
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associated with CICs is resistance to cytotoxic agents. This
resistance is attributed, in many cases, to increased expres-
sion of the ABCG2 multi-drug resistance transporter.
ABCG2 is capable of pumping a variety of substrates,
including cytotoxic drugs, out of the cell using ATP-
dependent mechanisms [25]. Expression of these transport-
ers is responsible, in part, for the common clinical problem
of multi-drug resistance [59] and may protect CICs from
cytotoxic agents used for cancer treatment. To model the
function of ABCG2 transporters, the DNA-intercalating dye
Hoechst 33342 has been used [25]. The efflux of this dye
allows the identification of a population of cells, known as
the side population (SP) by flow cytometric analysis. Goodell
et al. first described the SP for hematopoietic stem cells [60]
and the SP has subsequently been used to study the hierarchi-
cal organization of blood and other tissues. This functional





Sphere growth from 7/19 patient lung tumor samples (SCLC and NSCLC) with
varying frequency of CD133+ expression (0.6 % to 22.0 % of tumor cells that
were capable of forming spheres). CD133+ lung cancer spheres demonstrated
(1) expression of stemness genes such as OCT4 and NANOG, (2) self-renewal
potential, (3) proliferation and differentiation ability (with subsequent loss of
tumorigenic potential upon differentiation), (4) chemotherapy resistance, and
(5) ability to recapitulate tumor heterogeneity in vivo
[14]
Sphere growth from 10 NSCLC patient samples and five lung cancer cell lines
sorted for CD133+ expression
[13]
Sphere growth in 11 out of 15 lung adenocarcinoma malignant pleural effusion
patient samples. Compared to adherent cells, sphere cells were associated with
enhanced ALDH1 activity and Oct-4, Nanog, Notch3, and Stat3 mRNA expression
[19]
Chemoresistance In the human lung cancer cell line H460, drug-selected cells (doxorubicin, cisplatin,
or etoposide) demonstrated (1) spheroid formation; (2) self-renewal capacity and
ability to differentiate; (3) expression of CD133; (4) enrichment for SP cells;
(5) expression of embryonic stem cell markers, growth factor receptors, and
chemokine receptors; and (6) high tumorigenic and metastatic potential
[18]
Cell surface marker
CD133 (AC133, Prominin 1) From patient lung cancer tissue samples, compared to CD133− cells, CD133+ cells
displayed (1) enhanced expression of OCT4, (2) enhanced self-renewal ability,
(3) increased expression of ABCG2, (4) enhanced resistance to chemotherapy
and radiotherapy, (5) increased invasive ability, (6) increased in vivo
tumor-restoration and proliferative capacity, and (7) increased spheroid formation
[13]
From patient lung cancer tissue samples, compared to CD133− cells, CD133+ cells
displayed (1) enhanced tumorigenic potential in vivo and (2) enhanced expression
of ABCG2, CXCR4, α-6 integrin (CD49f), OCT4, and NANOG. CD133+ cells
demonstrated a self-renewal capacity in vitro, and cisplatin resistance in vitro and in vivo
[12]
CD44 Expression of CD44 (62 % to 96 % of tumor cells) in 6/10 human NSCLC lines
examined. Compared to CD44− cells, CD44+ cells displayed (1) spheroid formation,
(2) resistance to cisplatin treatment in vitro, (3) enhanced tumorigenicity in vivo,





In human lung cancer cell lines (H460, H23, HTB-58, A549, H441, and H2170),
compared to non-SP cells, SP cells demonstrated (1) enhanced invasiveness in vitro
and tumorigenicity in vivo, (2) enhanced ABCG2 and human telomerase reverse
transcriptase expression, and (3) resistance to multiple chemotherapy drugs
[15]
In human SCLC cells (NCI-H82, H146, and H526), SP expression comprised <1 %
of cells. Compared to non-SP cells, SP cells were associated with (1) higher proliferative
capacity; (2) efficient self-renewal capacity; (3) decreased expression of differentiated
cell markers; (4) enhanced tumorigenicity; and (5) expression of genes associated with CICs,




In human lung cancer cell lines ALDH1 activity was associated with (1) capacity
for proliferation; (2) self-renewal and differentiation; (3) resistance to chemotherapy;
(4) expression of CD133; and (5) enhanced tumorigenicity, as well as ability to
recapitulate the original tumor heterogeneity in vivo
[16]
From 303 clinical patient specimens and controls, overexpression was positively
correlated with stage and grade to tumor and associated with poorer prognosis
for patients with early-stage lung cancer
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property has also been used to study putative CICs from a
variety of human cancers, including acute myelogenous leu-
kemia as well as gliomas and neuroblastomas [61–63]. More
recently, SP cells have been the focus of research examining
lung CICs. Ho et al. demonstrated in a study of six human
lung cancer cell lines that cells in the SP exhibited properties
of CICs including (1) enhanced invasiveness and tumorige-
nicity, (2) increased expression of human telomerase reverse
transcriptase and ABCG2 expression, and (3) resistance to
chemotherapy [15]. Salcido et al. showed, in a study examin-
ing SP in three human SCLC cell lines, that compared to non-
SP cells, SP cells demonstrated (1) a higher proliferative
capacity, with efficient self-renewal capacity and decreased
expression of differentiated markers; (2) increased tumorige-
nicity; and (3) increased expression of self-renewal genes
such as SOX1/2, WNT1, MYC, and genes in the Notch and
Hedgehog pathways [42].
Another functional marker of interest for isolating and
characterizing CICs is aldehyde dehydrogenase-1 (ALDH1),
a cellular detoxifying enzyme that oxidizes a variety of intra-
cellular aldehydes to carboxylic acids [64]. The chemothera-
peutics cisplatin and cyclophosphamide generate toxic
aldehydes that are metabolized by ALDH1 [65]. High
ALDH1 activity has been demonstrated in hematopoietic
progenitor cells [66]. The activity of ALDH1 has also been
detected in both normal and malignant human mammary stem
cells and can be used to predict poor clinical outcomes in
breast cancer [67]. Ginestier et al. demonstrated that high
activity of ALDH1 identifies cells capable of self-renewal
and high tumorigenicity in an immunocompromised mouse
human tumor xenograft study [67]. In addition to hematopoi-
etic and breast, activity of ALDH1 has subsequently been
shown to enrich for normal stem cell populations or CICs in
various other organ systems including brain, colon, and pan-
creas [68–70]. Recently, the activity and expression of
ALDH1 has been correlated to the presence of lung CICs
and the aggressiveness of lung tumors [16]. Jiang et al. has
demonstrated using human NSCLC cell lines that cells
expressing active ALDH1 are associated with a capacity for
proliferation, self-renewal, and differentiation [16]. These
cells also displayed expression of the CIC marker CD133,
and CIC functional attributes of enhanced tumorigenicity and
resistance to chemotherapy. In the same report, overexpres-
sion of ALDH1 was reported to correlate with poor prognosis
for patients with early-stage NSCLC [16]. These findings
make ALDH1 activity an attractive functional marker for
identifying CICs, for use as a potential prognostic tool, and
for use as a therapeutic target.
Functional characteristics of lung CICs
CICs from various cancers have been shown to form
multicellular three-dimensional spheres, also termed
“tumorspheres” or “spheroids” when grown in vitro in non-
adherent, serum-free media conditions [10, 14, 71]. In these
conditions, most cells undergo a form of apoptosis known as
anoikis induced by anchorage-dependent cells detaching from
the surrounding extracellular matrix. However, rare anoikis-
resistant cells divide and generate heterogeneous spheroid
structures, composed of (1) cells that are differentiated and
not anoikis-resistant, and (2) rare long-term proliferating
anoikis-resistant cells—putative CICs. Sphere assays, and a
recent mathematical interpretation of the sphere assay, allow
for the assessment of the symmetric division expansion rate of
malignant stem cell-like cells, and the evaluation of the effects
of therapeutics on the self-renewal and proliferative activity of
these cells [72]. Sphere assays are therefore powerful tools to
assess the functional and phenotypic properties associated
with putative CIC populations. Eramo et al., in a study of
patient tumor samples, demonstrated sphere formation in sev-
en out of 19 lung cancers [14]. In this study, long-term sphere
culture was used to expand CICs for further analysis. Sphere-
derived cells were found to have in vitro and in vivo properties
of lung CICs including (1) self-renewal potential, (2) exten-
sive proliferation and differentiation capacity, (3) expression
of CD133, (4) expression of embryonic stemness genes such
as OCT4 and NANOG, and (5) chemotherapy resistance and
tumorigenicity. Mancini et al. have demonstrated sphere
growth in 11 out of 15 lung adenocarcinomamalignant pleural
effusion patient samples [19]. Compared to matched adherent
cells, sphere-derived cells demonstrated enhanced ALDH1
activity and expression of mRNA for Nanog, Notch3, Oct-4,
and STAT3. Despite the lack of sphere-forming capability for
all tumors evaluated in these studies, the in vitro sphere assay
is useful for characterizing and isolating CICs. Spheroid cul-
ture and demonstration of long-term self-renewal as spheres is
a routine trait characterized for putative lung CIC populations
in a number of additional studies [12, 13, 17, 18].
Chemoresistance and radiation resistance are another
functional characteristic associated with CICs. Chemoresist-
ance often goes hand in hand with expression of functional
markers such as SP expression, but warrants inclusion on its
own merit. Chemotherapy resistance and expression of the
SP/ABCG2 transporter has been used to enrich and charac-
terize CICs. Levina et al. characterized drug-selected H460
human lung cancer cells and showed that these cells have
characteristics of lung CICs including (1) sphere formation
and self-renewal capacity; (2) an undifferentiated phenotype
with an ability to differentiate; (3) expression of the SP,
CD133, embryonic stem cell markers, and growth factor
and chemokines receptors; and (4) a high tumorigenic and
metastatic potential [18]. Avariety of other studies have also
used chemoresistance as a functional characteristic for CIC
identification [12–17]. Less is known about radiation resis-
tance and lung CICs. The existence of a subpopulation of
radiation-resistant tumor cells has long been proposed by
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radiobiologists [73]. Characteristics of CICs that are thought
to play a role in radiation resistance include, among others,
(1) their relatively quiescent nature, (2) their capacity to
regenerate tumors from a small starting number of cells,
(3) more active DNA strand break repair pathways, and
(4) down-regulation of senescence pathway associated with
increased telomerase activity [74–77]. Addressing the
mechanisms that cells use to become the treatment-
resistant cell population may allow for specifically targeting
these cells and increase the effectiveness of treatment.
Demonstration of CIC phenotypic markers and function-
al characteristics in vitro is often validated in vivo by tumor
initiation studies. For human cancer cell lines/clinical sam-
ples, this is assessed through tumor formation from a limit-
ing dilution of cells in immunocompromised mice. As all
cells cannot induce tumors, the expansion of the resulting
tumors is suggested to be driven by CICs. However, inves-
tigating CICs using xenograft mouse models for human
tumor initiation is not without problems. Different strains
of immunocompromised mice exhibit differing levels and
types of residual immune effector cells. This in turn may
alter the efficiency of tumor cell engraftment, and therefore
the frequency or subpopulation of putative CICs may differ
depending on the strain of immunocompromised mouse
used. For instance, the detection frequency of tumorigenic
cells in a melanoma xenograft model has been shown to be
increased with the use of the NOD-SCIDγ (NSG, NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ) mouse compared to ordinary SCID
mice that retain some natural killer cell activity, with single
cell transplants capable of forming tumors in NSG mice
[78]. Furthermore, the immunocompromised mouse micro-
environment does not recapitulate the microenvironment in
a human patient with naturally occurring cancer. While xeno-
graft studies allow the identification of a sub-population of
cells able to recapitulate a tumor in an immunocompromised
mouse, they may not present an accurate picture of the char-
acteristics of CICs. In order for a tumor to form in humans,
potential CICs must interact with the immune system to
prevent tumor recognition and elimination. This interaction
is lost in immunocompromised xenografts. It has been sug-
gested that studies investigating the ability of different sub-
types of cells to grow in immunocompromised mice
demonstrates selection for cells that can best adapt to growth
in mouse tissue. Therefore, these studies might not be differ-
entiating true tumorigenic CICs from non-CICs. Alternatively,
immunocompetent syngeneic models allow for interactions of
the recipient mouse host immune system, a situation that more
closely models cancer in humans. Kelly et al. demonstrated
that tumor growth was not necessarily driven exclusively by
rare stem cell-like cells, when as few as 10 unsorted mouse
lymphoma cells were reported to transplant disease in synge-
neic recipient mice [79]. Recently, the tumorigenicity of lung
CICs have been assessed in syngeneic mice to better model
the interactions between the host immune system and CICs
[80]. Syngeneic models allow the examination of CIC-derived
cancer vaccines and immunotherapy, treatment that are unable
to be assessed in immunocompromised animals. These cav-
eats support the need for more rigorous testing of the cancer
stem/initiating cell hypothesis, and the development of mouse
models that either more closely recapitulates the human mi-
croenvironment for studying human cancer cells, or the use of
syngeneic mouse models to test CICs from murine cancers.
Targeting CICs
Resistance to chemotherapy and radiotherapy is thought to
be behind the regeneration of tumor following initially
successful treatment [81]. Compared to non-CICs, CICs
are likely slow dividing, more resistant to apoptosis, and
have an increased ability for DNA repair, making them more
resistant to traditional methods of cancer treatment (reviewed
in [74, 81]). This led to the hypothesis that therapies targeting
differentiated cells, but sparing CICs, result in tumor relapse,
while innovative treatments targeting CICs, but sparing dif-
ferentiated cells, might lead to tumor eradication (Fig. 1b).
Developing innovative treatments is an ambitious approach,
as different CICs will likely respond with varying sensitivities
to treatment. This is made more difficult by the lack of
universal and specific markers for CICs. Pre-clinically, the
sphere assay provides a model for assessing the treatment
efficacy on the self-renewal and proliferative activity of CICs
specifically that does not rely on identification of specific
markers [72]. This could provide a model for the high-
throughput assessment of various novel therapies targeting
CICs. Treatments targeting CICs discussed here include (1)
targeting pathways involved in self-renewal, (2) differentia-
tion therapy, (3) antibody-directed and other targeted therapies
for CICs, and (4) future directions for immunotherapy
approaches to target CICs.
Targeting CICs self-renewal pathways
There is increasing interest in investigating the self-renewal
pathways utilized by CICs as therapeutic targets and com-
bining these targeted CIC therapies with conventional treat-
ments. These pathways include Hh, Notch, and Wnt.
The use of cyclopamine, a steroid-like molecule, to in-
hibit the Hh signaling pathway has shown promise in inhib-
iting the growth of medulloblastoma, basal cell carcinoma,
and rhabdomyosarcoma [82, 83], and may find use in other
tumors that are associated with aberrant Hh signaling. In
SCLC, which has primitive features of pulmonary neuroen-
docrine cells, tumor development is dependent on activation
of Hh signaling. Hh signaling plays a role in the normal
differentiation of pulmonary neuroendocrine precursor cells
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and in the development of SCLC [84]. Hh pathway blockade
by cyclopamine has demonstrated growth arrest and increased
apoptosis for SCLC [84]. Therefore, some lung cancers may
be susceptible to antagonists of the Hh pathway. A semi-
synthetic derivative of cyclopamine, IPI-926, is currently
undergoing clinical trials for various tumors [85].
Inhibition of Notch signaling can be accomplished at
many different levels (reviewed in [86]) including, among
others, the use of (1) receptor decoys that interfere with
Notch/ligand interactions, (2) γ-secretase inhibitors to block
Notch activation through proteolytic cleavage of the recep-
tor by γ-secretase protein complex, and (3) antibodies that
interfere with Notch signaling. In the case of lung cancer,
inhibition of Notch signaling, in some NSCLC lines, has
shown evidence of increasing apoptosis and decreasing
tumor growth [87, 88], potentially through blocking the
self-renewal efficiency of CICs. Haruki et al. demonstrated
that a dominant-negative Notch-3 receptor, capable of inhib-
iting the Notch-3 pathway, was effective in reducing soft
agar growth of human lung cancer lines and sensitized these
lines to subsequent EGF receptor tyrosine kinase inhibition
treatment [87]. Konishi et al. demonstrated that MRK-003, a
gamma-secretase inhibitor, inhibited Notch-3 signaling and
subsequently reduced growth and increased apoptosis of
human lung cancer cell lines in vitro and in vivo using
xenograft models [88]. Assessment of antibodies directed
against Notch signaling is ongoing with results showing
tumor inhibition and inhibition of cell fate decisions such
as self-renewal in adult stem/progenitor cells [86].
The Wnt pathway can be inhibited through a variety of
mechanisms. Targeting of β-catenin has received attention
with retinoic acid (RA) [89] and tyrosine kinase inhibitors
such as imatinib [90, 91] being shown to down-regulate β-
catenin signaling. A monoclonal antibody directed against
Wnt-1 has demonstrated an effect against a NSCLC cell line
in vitro through inhibiting the Wnt/β-catenin signaling path-
way and induction of apoptosis [92]. This monoclonal anti-
body also suppressed tumor growth in vivo for both non-
established tumors and already established tumors.
The effect these treatments may have on somatic stem
cells and other normal cells has to be weighed against their
treatment efficacy against CICs. Targeted therapy against
self-renewal pathway signaling molecules used by CICs
may hold promise as a treatment, but to determine which
patients are likely to benefit from treatment molecular tests
assessing the signaling pathways activated in an individual
tumor needs to be explored. This may be possible on a
routine clinical basis as the cost of whole tumor genome
expression analysis continues to fall. Designing rational
treatment regimens targeting signaling pathways needs to
be incorporated into current treatments to most effectively
ablate self-renewal capacity in CICs and induce apoptosis of
these cells leading to reduction in tumor burden.
Targeting CICs using differentiation therapy
Another approach to target CICs is the induction of their
differentiation, resulting in the loss of their ability for self-
renewal and tumor maintenance. RA is one therapy used in
the clinic to promote differentiation of epithelial cells [82].
RA-based therapy followed by chemotherapy has been used
in acute promyelocytic leukemia and could also find use in
solid tumor therapy [93]. The TGF-β superfamily member
BMP-4 has been utilized to differentiate human glioblasto-
ma stem cell-like CICs, with subsequent reduction in pro-
liferation and induction of differentiation markers noted
[94]. Recently, Azzi et al. demonstrated the use of interleu-
kin (IL)-15 in the differentiation of renal CICs, resulting in
the decrease of the CIC pool and generating differentiated
non-tumorigenic cells that are susceptible to treatment with
chemotherapy [95]. The use of IL-15 as a differentiation
therapy is interesting in light of its other roles as an immune-
regulating and anti-cancer cytokine [96]. Inducing differen-
tiation in lung CICs may hold promise as a novel treatment
approach.
Targeting CICs using antibody-directed and other targeted
therapies
Antibody therapy directed specifically to CICs may find use
in the clinic (Fig. 2a). The use of monoclonal antibodies
(mAbs) targeting CICs is a relatively new approach. CICs
are typically present in low frequency compared to non-
CICs (typical estimates range between 0.1 % and 10 % of
all tumor cells), and markers identifying CICs are not well
characterized. Additionally, cell surface markers that have
been characterized are not uniformly expressed by all CICs
and often overlap with normal stem cells or non-tumorigenic
cells. Identification of novel markers on CICs, preferably
not expressed or with low expression on somatic stem cells
or non-tumor cells, would be ideal. Additionally, therapy
may be against the CIC itself (direct therapy) or against cells
that maintain the CIC niche in the tumor (indirect therapy).
Direct mAb therapy specifically targeting lung CICs has
not been well studied. However, two of the markers
expressed by putative lung CICs, CD133 and CD44, do
have the potential to be targeted through mAb therapy.
AC133 is a mAb that recognizes CD133. In a pre-clinical
study, AC133 conjugated to a cytotoxic drug was used to
target hepatocellular cancer cells in vitro and in vivo with
demonstration of tumor growth inhibition [97]. Similarly, an
antibody directed against CD44, H90, has demonstrated
efficacy in an AML model by specifically targeting CICs
leading to promotion of differentiation, and inhibition of
tumor proliferation and niche localization [98]. CD44 is a
molecule with multiple variants, and future characterization
of these variants is necessary for production of ideal mAbs
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for specific tumor types. Development of strategies to spe-
cifically target CD44/hyaluronan axis is ongoing (reviewed
in [99]).
Stem cell niches are locations in a tissue that specifically
support somatic stem cells and allow the repopulation of the
stem cell compartment from stem cells or differentiated cells
if the stem cell compartment is depleted [20]. Similarly, a
tumor CIC niche specifically supports CICs. Therefore, it is
possible that therapy that disrupts the tumor CIC niche
could lead to the subsequent eradiation of CICs. Alterna-
tively, tumor therapy that depletes CICs, but does not erad-
icate the tumor CIC niche, could lead to repopulation of the
CIC pool.
Vascular endothelial cells are a component of the neural
stem cell niche [100], and inhibitors of vascular endothelial
growth factor (VEGF) have shown promise in ablating
CICs, in addition to decreasing tumor vascularization, in a
xenograft model of glioblastoma [101]. Anti-vasculature
therapies include anti-VEGF antibodies (bevacizumab),
anti-EGFR antibodies (cetuximab), and small molecules
such as erlotinib that act on EGFR. CICs have been reported
to express higher amounts of VEGF in both normoxic and
hypoxic conditions compared to non-CICs. In a glioma
model, high VEGF expression has been shown to lead to
increased endothelial cell migration and tube formation,
both of which can be subsequently blocked with bevacizumab
[102].
Cells bearing the CXCR4 receptor molecule are capable
of homing to specific niche environments via responding to
a signal gradient of stromal cell-derived factor-1 (SDF-1/
CXCL12). CXCR4 has been demonstrated to play a role in
metastatic and drug-resistant lung CICs [103, 104] and is
up-regulated in drug-selected lung CICs [18]. Thus, antag-
onists of the CXCR4/CXCL12 axis, such as Plerixafor
Fig. 2 Targeted therapy for CICs. a CICs are likely to express specific
markers (cell surface antigens in the example shown) that can be used
for targeted therapy. One approach will be treatment with monoclonal
antibodies (mAb) specific for markers expressed on CICs but not on
differentiated cells. Through a variety of mechanisms, mAb therapy
can lead to interference in cell growth or regulation of CICs or can
induce apoptosis or cell killing directly. b Further characterization of
lung CICs will likely reveal expressed antigens that can be used to
target them. One cancer vaccine approach to eliminate CICs is shown
here using antigen-presenting dendritic cells (DCs) pulsed with tumor-
associated antigen (TAA) epitopes specific for CICs. DCs process and
present TAA on major histocompatibility complexes (MHC) to T cells
to stimulate a CD8+ cytotoxic T-lymphocyte (CTL) response that is
thought to be critical for tumor elimination. DCs also express all of the
necessary cytokine and co-stimulatory molecules, such as IL-12, to
further direct the immune response to tumor and induce CD4+ Th1 T-
helper cells. Once CICs are eliminated from the tumor the capacity for
self-renewal is lost and the tumor degenerates. Note that tumor debulk-
ing of differentiated cells will also need to be accomplished
concurrently
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(AMD3100) and T140 analogs (TN14003/BKT140), are of
therapeutic interest for blocking metastatic disease, sensitiz-
ing tumor cells to chemotherapy, and targeting lung CICs
[105].
Several mAbs have been utilized that neutralize autocrine
signaling mediators involved in CIC growth and resistance
to chemotherapy. In a preclinical model, an anti-IL-3 recep-
tor alpha chain (CD123) neutralizing antibody demonstrated
impairment of homing of leukemic CICs to the bone mar-
row, and a reduction in AML burden for mice with pre-
established disease [106]. In a solid tumor model, an anti-
IL-4 neutralizing antibody has been characterized for the
ability to impair CICs in colorectal cancer [107, 108].
Todaro et al. demonstrated that CD133+ colon CICs utilize
IL-4 to protect themselves from apoptosis, and that an anti-
IL-4 neutralizing antibody will selectively sensitize these
CICs to subsequent chemotherapy, thereby enhancing anti-
tumor efficacy [107].
CICs are similar to normal somatic stem cells in many
regards, meaning some treatments aimed at targeting CICs
might put somatic stem cells at risk. ABC transporter (SP
cells) inhibitors used in combination with chemotherapy
have been shown to increase the efficacy of chemotherapy
targeting CICs [81]. Also, an anti-ABCB5 antibody has
been used to treat melanoma in a xenograft model resulting
in reduction in tumor size and tumor eradication in 70 % of
treated animals [109]. The proposed mechanism for this
action was antibody-dependent cellular cytotoxicity (ADCC)
directed against CICs. However, treatments targeting ABC
transporters could also affect somatic stem cells, leading to
potential toxicity in the bone marrow and improper mainte-
nance of the blood–brain barrier [110].
Additional approaches exist to target CICs and these new
strategies are the focus of ongoing research. Histone deace-
tylase inhibitors and other epigenetic-acting drugs are po-
tentially useful for targeting CICs [111], as are small
molecule inhibitors targeting key proteins in the intrinsic
apoptotic pathway, a pathway often altered in CICs [112,
113]. Similarly, the knock-down of the “stemness” tran-
scription factor Oct-4 has been shown to lead to apoptosis
in CIC-like cells in a murine model of lung cancer [114].
Targeting CICs using immunotherapy
Immunotherapy strategies utilize the patient’s own immune
system in the treatment of cancer by inducing or enhancing
(activation immunotherapies) immune responses to tumor or
by suppressing (suppression immunotherapies) immune
responses that are blocking effective tumor targeting. One
promising activation immunotherapy strategy is the use of
dendritic cell (DC) vaccines. DCs are powerful antigen-
presenting cells that play a central role in initiating and
directing immune responses through the processing of
antigens and presentation of epitopes in the context of
surface MHC molecules to T cells. DCs are equipped with
all of the necessary co-stimulatory and cytokine signals to
stimulate cytolytic T-lymphocyte (CTL) responses to tumor-
associated antigens (TAA), leading to the elimination of
tumors expressing these antigens (Fig. 2b). Cancer vaccines
targeting solid tumors have been employed, with varying
success, both pre-clinically and clinically in the treatment of
cancer [115]. Several clinical trials have examined the effi-
cacy of epitope-modified DCs, often accomplished by
“pulsing” DCs ex vivo with synthetic TAA peptides [116,
117]. One drawback of peptide loading is the need for
knowledge of the antigen sequence and the requirement
for favorable binding affinity of the peptide for MHC. An
alternative strategy is to load DCs with protein lysates
generated from tumors. Tumor lysates, however, contain
many antigens, most of which are not tumor specific.
Vaccine approaches that specifically target CIC antigens,
and therefore CICs, may be more successful [118]. In a pre-
clinical trial using irradiated CICs as antigens for a DC
vaccine for glioblastoma, activation of antigen specific T
cells and γ-interferon production was seen in the vaccinated
animals [119]. These immune responses were correlated
with prolonged survival in animals bearing tumor compared
to an equivalent vaccine derived from non-CICs. In another
pre-clinical study targeting murine CT26 colon cancer, Mori
et al. compared vaccination against TAA expressed by CIC
versus those expressed by non-CIC. Vaccination against
non-CIC antigens did not induce an anti-tumor response
whereas vaccination against antigens expressed on CIC led
to a significant antitumor response [120]. These results
highlight the importance of targeting antigens on CICs for
an effective vaccine strategy.
Concluding remarks
Investigating CICs are not without potential difficulties,
including among others, (1) defining CICs and their
markers, (2) the use xenotransplantation models, (3) identi-
fying and measuring CIC stemness, and (4) the challenge of
developing therapies that specifically target CICs (for a
review of these see [121]). Studying lung CIC may have a
major impact on cancer treatment by suggesting novel ther-
apeutic approaches; however, additional studies are still
required to further characterize the plasticity, heterogeneity,
immune-modulating properties, and functional/physical
phenotype of lung CICs. These studies will aid in identify-
ing therapies that can specifically target lung CICs. Prospec-
tive clinical investigations assessing putative lung CIC
markers and functional characteristics should be performed,
with a focus on assessing cells with these characteristics
before, during, and after treatment. In addition to suggesting
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new targets for therapy, these studies may provide diagnos-
tic and prognostic information. Targeted therapy against
CICs may need to be personalized for each patient, either
through assessing the appropriate mAb or differentiation
therapy required for their particular CIC phenotype, or
through application of immunotherapy. To be effective,
new therapies targeting CICs will need to be incorporated
into clinical practice alongside traditional therapies that
debulk the tumor and therapies that aim to interfere with
the supportive niche of CICs, including anti-angiogenic or
anti-stroma therapy. In this setting, the development of
targeted CIC therapies could lead to meaningful increases
in clinical responses.
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